Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1990 Jul 15;143(2):101–107.

HIV antibody screening among immigrants: a cost-benefit analysis.

H Zowall 1, R D Fraser 1, N Gilmore 1, A Deutsch 1, S Grover 1
PMCID: PMC1452105  PMID: 2114210

Abstract

To assess the economic impact of HIV (human immunodeficiency virus) antibody screening among potential immigrants on Canada's health care system we estimated the costs and benefits of such screening among the 160 135 immigrants who entered Canada in 1988 using the in-hospital costs of treating AIDS (acquired immune deficiency syndrome) over the 10 years after immigration. This economic model was based on current international HIV seroprevalence data, Canadian immigration statistics and estimates of disease progression. Between 343 and 862 of the immigrants were estimated to have been HIV seropositive; with the use of the enzyme-linked immunosorbent assay and the Western blot technique 310 to 780 of them would have been correctly identified as being seropositive, and 33 to 82 would have been incorrectly classified as being seronegative. Another 16 would have been falsely classified as being seropositive. There would have been 151 to 379 cases of AIDS from 1988 to 1998 among the immigrants identified as being HIV-positive. The estimated total cost of screening would have been $3.3 to $3.4 million. The in-hospital costs of treating HIV-infected immigrants in whom AIDS developed between 1989 and 1998 would have been $5.0 to $17.1 million. Accordingly, screening would have saved $1.7 to $13.7 million over the 10 years after immigration. However, we do not advocate screening on the basis of economic analysis alone and acknowledge that any policy regarding such screening must also incorporate social, legal and ethical considerations.

Full text

PDF
103

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chang R. S., Chan R. C., French G. L., Leong S., Mak K. H., Carlson J. R., Yee J., Gardner M. B. HTLV-III antibody testing in Hong Kong. JAMA. 1986 Jul 4;256(1):41–41. [PubMed] [Google Scholar]
  2. Cleary P. D., Barry M. J., Mayer K. H., Brandt A. M., Gostin L., Fineberg H. V. Compulsory premarital screening for the human immunodeficiency virus. Technical and public health considerations. JAMA. 1987 Oct 2;258(13):1757–1762. [PubMed] [Google Scholar]
  3. Clumeck N., Robert-Guroff M., Van de Perre P., Jennings A., Sibomana J., Demol P., Cran S., Gallo R. C. Seroepidemiological studies of HTLV-III antibody prevalence among selected groups of heterosexual Africans. JAMA. 1985 Nov 8;254(18):2599–2602. [PubMed] [Google Scholar]
  4. Curran J. W., Jaffe H. W., Hardy A. M., Morgan W. M., Selik R. M., Dondero T. J. Epidemiology of HIV infection and AIDS in the United States. Science. 1988 Feb 5;239(4840):610–616. doi: 10.1126/science.3340847. [DOI] [PubMed] [Google Scholar]
  5. Dayrit M. M., Monzon O. T., Basaca-Sevilla V., Hayes C. G. Emerging patterns of HIV infection and control in the Philippines. West J Med. 1987 Dec;147(6):723–725. [PMC free article] [PubMed] [Google Scholar]
  6. Denis F., Barin F., Gershy-Damet G., Rey J. L., Lhuillier M., Mounier M., Leonard G., Sangare A., Goudeau A., M'Boup S. Prevalence of human T-lymphotropic retroviruses type III (HIV) and type IV in Ivory Coast. Lancet. 1987 Feb 21;1(8530):408–411. doi: 10.1016/s0140-6736(87)90118-8. [DOI] [PubMed] [Google Scholar]
  7. Eisenstaedt R. S., Getzen T. E. Screening blood donors for human immunodeficiency virus antibody: cost-benefit analysis. Am J Public Health. 1988 Apr;78(4):450–454. doi: 10.2105/ajph.78.4.450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gauthier D. K., Turner J. G. Anti-HIV antibody testing: procedures and precautions. Am J Infect Control. 1989 Aug;17(4):213–225. doi: 10.1016/0196-6553(89)90131-4. [DOI] [PubMed] [Google Scholar]
  9. Guo H. Y., Chang R. S., Li H. Y., Yao Z. L., Guan Z. J., Lin B. F., Gardner M. B. Antibody against the human immunodeficiency virus in Guangdong Province, China. JAMA. 1986 Nov 7;256(17):2343–2344. [PubMed] [Google Scholar]
  10. HIV infection in the Dominican Republic. JAMA. 1987 Jul 3;258(1):46–47. [PubMed] [Google Scholar]
  11. Haseltine W. A. Silent HIV infections. N Engl J Med. 1989 Jun 1;320(22):1487–1489. doi: 10.1056/NEJM198906013202210. [DOI] [PubMed] [Google Scholar]
  12. Hay J. W., Osmond D. H., Jacobson M. A. Projecting the medical costs of AIDS and ARC in the United States. J Acquir Immune Defic Syndr. 1988;1(5):466–485. [PubMed] [Google Scholar]
  13. Ijsselmuiden C. B., Steinberg M. H., Padayachee G. N., Schoub B. D., Strauss S. A., Buch E., Davies J. C., de Beer C., Gear J. S., Hurwitz H. S. AIDS and South Africa--towards a comprehensive strategy. Part II. Screening and control. S Afr Med J. 1988 Apr 16;73(8):461–464. [PubMed] [Google Scholar]
  14. John T. J., Babu P. G., Jayakumari H., Simoes E. A. Prevalence of HIV infection in risk groups in Tamilnadu, India. Lancet. 1987 Jan 17;1(8525):160–161. doi: 10.1016/s0140-6736(87)91992-1. [DOI] [PubMed] [Google Scholar]
  15. Kanki P. J., M'Boup S., Ricard D., Barin F., Denis F., Boye C., Sangare L., Travers K., Albaum M., Marlink R. Human T-lymphotropic virus type 4 and the human immunodeficiency virus in West Africa. Science. 1987 May 15;236(4803):827–831. doi: 10.1126/science.3033826. [DOI] [PubMed] [Google Scholar]
  16. Keystone J. S., Keystone J. S., Keystone J. S. Imported intestinal parasites: a growing problem? Can Med Assoc J. 1981 Sep 1;125(5):415-6, 450. [PMC free article] [PubMed] [Google Scholar]
  17. Koenig R. E., Pittaluga J., Bogart M., Castro M., Nunez F., Vilorio I., Delvillar L., Calzada M., Levy J. A. Prevalence of antibodies to the human immunodeficiency virus in Dominicans and Haitians in the Dominican Republic. JAMA. 1987 Feb 6;257(5):631–634. [PubMed] [Google Scholar]
  18. Mann J. M., Bila K., Colebunders R. L., Kalemba K., Khonde N., Bosenge N., Nzilambi N., Malonga M., Jansegers L., Francis H. Natural history of human immunodeficiency virus infection in Zaire. Lancet. 1986 Sep 27;2(8509):707–709. doi: 10.1016/s0140-6736(86)90229-1. [DOI] [PubMed] [Google Scholar]
  19. Okpara R. A., Akinsete I., Williams E. E., Schneider J., Wendler I., Hunsmann G. Antibodies to human immunodeficiency virus (HTLV-III/LAV) in people from Lagos and Cross River States of Nigeria. Acta Haematol. 1988;79(2):91–93. doi: 10.1159/000205728. [DOI] [PubMed] [Google Scholar]
  20. Okware S. I. Towards a national AIDS-control program in Uganda. West J Med. 1987 Dec;147(6):726–729. [PMC free article] [PubMed] [Google Scholar]
  21. Piot P., Plummer F. A., Mhalu F. S., Lamboray J. L., Chin J., Mann J. M. AIDS: an international perspective. Science. 1988 Feb 5;239(4840):573–579. doi: 10.1126/science.3277271. [DOI] [PubMed] [Google Scholar]
  22. Ransohoff D. F., Feinstein A. R. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med. 1978 Oct 26;299(17):926–930. doi: 10.1056/NEJM197810262991705. [DOI] [PubMed] [Google Scholar]
  23. Risk factors for AIDS among Haitians residing in the United States. Evidence of heterosexual transmission. The Collaborative Study Group of AIDS in Haitian-Americans. JAMA. 1987 Feb 6;257(5):635–639. doi: 10.1001/jama.1987.03390050061019. [DOI] [PubMed] [Google Scholar]
  24. Tamashiro H., Kawaguchi Y. AIDS prevention and control in Japan. West J Med. 1987 Dec;147(6):719–722. [PMC free article] [PubMed] [Google Scholar]
  25. de Medina M., Fletcher M. A., Valledor M. D., Ashman M., Gordon A. M., Schiff E. R. Serological evidence for HIV infection in Cuban immigrants in 1980. Lancet. 1987 Jul 18;2(8551):166–166. doi: 10.1016/s0140-6736(87)92374-9. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES